IS2041B - Skuggamagnandi myndgreiningaraðferð til þess að fylgjast með inngripsmeðferð - Google Patents

Skuggamagnandi myndgreiningaraðferð til þess að fylgjast með inngripsmeðferð

Info

Publication number
IS2041B
IS2041B IS5399A IS5399A IS2041B IS 2041 B IS2041 B IS 2041B IS 5399 A IS5399 A IS 5399A IS 5399 A IS5399 A IS 5399A IS 2041 B IS2041 B IS 2041B
Authority
IS
Iceland
Prior art keywords
tissue
contrast
state
imaging method
shadow
Prior art date
Application number
IS5399A
Other languages
English (en)
Other versions
IS5399A (is
Inventor
B. Lauffer Randall
O. Dunham Stephen
Original Assignee
Epix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Pharmaceuticals, Inc. filed Critical Epix Pharmaceuticals, Inc.
Publication of IS5399A publication Critical patent/IS5399A/is
Publication of IS2041B publication Critical patent/IS2041B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Transforming Light Signals Into Electric Signals (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IS5399A 1997-10-02 2000-03-10 Skuggamagnandi myndgreiningaraðferð til þess að fylgjast með inngripsmeðferð IS2041B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94298997A 1997-10-02 1997-10-02
PCT/US1998/020182 WO1999017809A2 (en) 1997-10-02 1998-09-24 Contrast-enhanced diagnostic imaging method for monitoring interventional therapies

Publications (2)

Publication Number Publication Date
IS5399A IS5399A (is) 2000-03-10
IS2041B true IS2041B (is) 2005-09-15

Family

ID=25478927

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5399A IS2041B (is) 1997-10-02 2000-03-10 Skuggamagnandi myndgreiningaraðferð til þess að fylgjast með inngripsmeðferð

Country Status (19)

Country Link
US (2) US6861045B1 (is)
EP (1) EP1019094B1 (is)
JP (2) JP2001518523A (is)
KR (1) KR20010030854A (is)
AT (1) ATE254479T1 (is)
AU (1) AU742438C (is)
BR (1) BR9812716A (is)
CA (1) CA2303426C (is)
DE (1) DE69819925T2 (is)
DK (1) DK1019094T3 (is)
ES (1) ES2206996T3 (is)
HU (1) HUP0101245A3 (is)
IL (1) IL134985A0 (is)
IS (1) IS2041B (is)
NO (1) NO321966B1 (is)
NZ (1) NZ503402A (is)
PT (1) PT1019094E (is)
SK (1) SK4842000A3 (is)
WO (1) WO1999017809A2 (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495118B1 (en) 1997-09-26 2002-12-17 Schering Aktiengesellschaft Lipophilic metal complexes for necrosis and infarction imaging
EP1019094B1 (en) * 1997-10-02 2003-11-19 Epix Medical, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
EP1237593A1 (en) 1999-11-22 2002-09-11 Epix Medical, Inc. Imaging sexual response
AU2001231090A1 (en) * 2000-01-22 2001-07-31 Epix Medical, Inc. Magnetic resonance imaging using contrast agents bioactivated by enzymatic cleavage
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US7186797B2 (en) * 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
WO2003074005A2 (en) 2002-03-01 2003-09-12 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US20050214859A1 (en) 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
WO2005110495A1 (en) * 2004-05-18 2005-11-24 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy control in radiation therapy with proton or ion beams
US7585492B2 (en) 2004-05-18 2009-09-08 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101317100A (zh) * 2005-11-29 2008-12-03 皇家飞利浦电子股份有限公司 使用磁共振区分结合和未结合造影剂
WO2007073792A1 (de) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung von 4,4-diphenylcyclohexanol
JP5563299B2 (ja) * 2006-08-17 2014-07-30 エピックス ファーマシューティカルズ，インコーポレイテッド リンパ系撮像方法
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
US20100092389A1 (en) * 2008-10-10 2010-04-15 The General Hospital Corporation Detection of atherosclerosis using indocyanine green
US9423480B2 (en) * 2008-10-27 2016-08-23 The University Of Western Ontario System and method for magnetic resonance imaging
WO2010108063A1 (en) 2009-03-19 2010-09-23 Wyeth Llc Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
RU2559930C2 (ru) 2010-02-02 2015-08-20 Конинклейке Филипс Электроникс Н.В. Формирование функциональных изображений
AU2012282678B2 (en) 2011-07-11 2016-03-03 California Institute Of Technology Akt-specific capture agents, compositions, and methods of using and making
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
WO2014165990A1 (en) 2013-04-08 2014-10-16 Sunnybrook Research Institute System and method for imaging biomarkers indicative of cardiac thermal ablation lesions
JP2015087167A (ja) * 2013-10-29 2015-05-07 キヤノン株式会社 画像処理方法、画像処理システム
US10314648B2 (en) 2013-12-13 2019-06-11 The Trustees of the Universoty of Pennsylvania Coaxial ablation probe and method and system for real-time monitoring of ablation therapy
WO2015171543A1 (en) 2014-05-05 2015-11-12 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
US10471162B2 (en) 2014-06-20 2019-11-12 The General Hospital Corporation Collagen targeted imaging probes
US9913875B2 (en) 2015-03-16 2018-03-13 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
WO2017011769A2 (en) 2015-07-15 2017-01-19 California Institute Of Technology Il-17f-specific capture agents, compositions, and methods of using and making
US10383590B2 (en) 2015-09-28 2019-08-20 General Electric Company Methods and systems for adaptive scan control
WO2018064597A1 (en) 2016-09-29 2018-04-05 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
WO2018085375A1 (en) 2016-11-01 2018-05-11 Ohio State Innovation Foundation Methods for the iodination of biomolecules
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
US20190370956A1 (en) 2018-05-30 2019-12-05 General Electric Company Contrast imaging system and method
WO2020093055A2 (en) 2018-11-02 2020-05-07 Indi Molecular, Inc. Peptide libraries with non-canonical amino acids
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
IL297806A (en) 2020-04-30 2022-12-01 Sairopa B V Anti-cd103 antibodies
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250285A (en) 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
IT1269839B (it) 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
CA2539215A1 (en) 1995-02-01 1996-08-08 Epix Pharmaceuticals, Inc. Diagnostic imaging contrast agents with extended blood retention
TW319763B (is) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19529512C2 (de) 1995-08-10 2000-11-23 Siemens Ag Verfahren zur Phasenkontrast-MR-Angiographie und Anordnung zur Durchführung des Verfahrens
DE19543785A1 (de) 1995-11-24 1997-05-28 Philips Patentverwaltung MR-Verfahren und Anordnung zur Durchführung des Verfahrens
BR9708470A (pt) * 1996-04-01 1999-04-13 Epix Medical Inc Agentes de contraste bioativados para formação de imagem para diagnósticos
IT1283650B1 (it) 1996-08-02 1998-04-23 Bracco Spa Chelati paramagnetici ad alta relassivita' in siero
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
EP1019094B1 (en) * 1997-10-02 2003-11-19 Epix Medical, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza

Also Published As

Publication number Publication date
EP1019094B1 (en) 2003-11-19
BR9812716A (pt) 2000-08-22
AU9668698A (en) 1999-04-27
NO20001707D0 (no) 2000-04-03
US20050118103A1 (en) 2005-06-02
DE69819925D1 (de) 2003-12-24
CA2303426A1 (en) 1999-04-15
HUP0101245A2 (hu) 2001-08-28
NO20001707L (no) 2000-05-31
KR20010030854A (ko) 2001-04-16
WO1999017809A3 (en) 1999-05-20
AU742438B2 (en) 2002-01-03
JP2001518523A (ja) 2001-10-16
NZ503402A (en) 2002-03-01
NO321966B1 (no) 2006-07-31
AU742438C (en) 2003-05-22
DE69819925T2 (de) 2004-09-02
IL134985A0 (en) 2001-05-20
HK1030744A1 (en) 2001-05-18
ES2206996T3 (es) 2004-05-16
JP2006077020A (ja) 2006-03-23
ATE254479T1 (de) 2003-12-15
DK1019094T3 (da) 2004-02-16
US7175829B2 (en) 2007-02-13
IS5399A (is) 2000-03-10
EP1019094A2 (en) 2000-07-19
SK4842000A3 (en) 2000-11-07
US6861045B1 (en) 2005-03-01
HUP0101245A3 (en) 2003-10-28
PT1019094E (pt) 2004-03-31
WO1999017809A2 (en) 1999-04-15
CA2303426C (en) 2008-09-23

Similar Documents

Publication Publication Date Title
IS2041B (is) Skuggamagnandi myndgreiningaraðferð til þess að fylgjast með inngripsmeðferð
BR9708470A (pt) Agentes de contraste bioativados para formação de imagem para diagnósticos
HUP0202635A2 (hu) Multimer leképzőszerek, eljárás ezek célbajuttatására multilocusos kötés útján és alkalmazásuk
WO2003005887A3 (en) System and methods for determining nerve proximity, direction, and pathology during surgery
EP1716871A3 (en) Diagnostic imaging contrast agents with extended blood retention
WO1994012095A3 (en) Apparatus for diagnostic imaging
ATE335515T1 (de) Morpholinobildgebung und therapie
ATE384519T1 (de) Hemmer-darstellende mittel
NO965301D0 (no) 2,4,6-trijod-5-substituerte-amino-isoftalatestere nyttige som röntgenkontrastmidler for medisinsk diagnostisk billeddannelse
EA199800881A1 (ru) Способ т1 - взвешенной магниторезонансной визуализации органов ретикуло-эндотелиальной системы
EP2202241A3 (en) Therapeutic compounds and methods for modulating V3, a versican isoform
WO2003013616A8 (en) Ionic and non-ionic radiographic contrast agents for use in combined x-ray and nuclear magnetic resonance diagnostics
DE69732370D1 (de) Spinresonanz kontrastmittel für das blut
Neuhaus The Role of Sphincterotomy in The Management of Common Bile Duct Stones
FR2766728B1 (fr) Dispositif anti-vibration pour instrument de jeu de balle